PCN169 Differences in the Use of Innovative Anti-Cancer Drugs Among French Hospitals

Value in Health - United Kingdom
doi 10.1016/j.jval.2011.08.1269
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Prm112 - Incorporation of Anti-Cancer Drugs Adverse Events in Health Economic Opinions of the French National Authority for Health (Has)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Was It Worth Introducing Health Economic Evaluation of Innovative Drugs in the French Regulatory Setting? The Case of New Hepatitis C Drugs

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2019English

Target-Based Anti-Cancer Drugs

Drug Delivery System
Pharmaceutical Science
2004English

Ethics Codes and Use of New and Innovative Drugs

British Journal of Clinical Pharmacology
Pharmacology
2019English

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Breast Cancer Risk: Differences by Molecular Subtype

Cancer Causes and Control
Cancer ResearchOncology
2011English

Repurposed Anti-Cancer Drugs: The Future for Anti-Infective Therapy?

Expert Review of Anti-Infective Therapy
VirologyInfectious DiseasesMicrobiology
2020English

Sex Differences in the Use of Asthma Drugs: Cross Sectional Study

BMJ
1998English

Aspects Regarding the Use of Drugs Among Athletes

Timisoara Physical Education and Rehabilitation Journal
2018English

Dna Damage Mechanisms of Anti-Cancer Drugs

Middle East Journal of Science
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy